Effects of local treatment with salmeterol and terbutaline on anti-IgE-induced wheal, flare, and late induration in human skin.
The capacity of terbutaline and the long-acting beta 2-agonist salmeterol to suppress wheal-and-flare reactions (WFRs) to intradermal antihuman IgE and to histamine was evaluated in 36 healthy volunteers. We also examined effects of the two drugs on the subsequent late cutaneous reaction (LCR) to anti-IgE. Salmeterol (10(-10)-10(-6) M) and terbutaline (10(-10)-10(-5) M), injected intradermally 2 or 15 min before anti-IgE challenge, produced a dose-dependent inhibition of the WFRs to anti-IgE (titer 1 : 10000) with a maximal effect of approximately 60% (wheal) and approximately 75% (flare) by both drugs. On a molar basis, salmeterol was approximately 10-100 times more potent than terbutaline in inhibiting the WFRs. Moreover, the wheal response to histamine (4 nmol) was antagonized by approximately 40% after pretreatment with either salmeterol (10(-5) M) or terbutaline (10(-4) M). We found that both salmeterol and terbutaline exhibited anti-WFR activity for up to 24 h, salmeterol being significantly more potent in this regard. When selecting a 15-min pretreatment interval with equieffective anti-WFR doses from the first dose-response experiments (i.e., a salmeterol: terbutaline ratio of 1 : 10), the WFRs to high-dose anti-IgE (titer 1 : 100) were inhibited by terbutaline (10(-5) M) by 25-30%, but not by salmeterol (10(-6)). On the other hand, salmeterol attenuated (by up to approximately 35%) the subsequent LCR more effectively than terbutaline. As compared to the pretreatment procedure, infiltration of the drugs (single doses) into the wheals 30 min after challenge with anti-IgE (titer 1 : 100) proved to be less effective on the development of LCRs. Taken together, salmeterol was found to express higher potency and have longer duration of action than terbutaline in inhibition of IgE-mediated inflammation in human skin.
Department of Respiratory and Allergic Diseases, Huddinge University Hospital, Karolinska Institute, Sweden.
R
R
Grönneberg
J
J
Raud
D000318:Adrenergic beta-Agonists / Q000627:therapeutic use*; D000328:Adult; D000420:Albuterol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D000888:Antibodies, Anti-Idiotypic / Q000009:adverse effects; D004305:Dose-Response Relationship, Drug; D005260:Female; D006632:Histamine / Q000009:adverse effects; D006801:Humans; D007271:Injections, Intradermal; D008297:Male; D008875:Middle Aged; D011292:Premedication; D000068299:Salmeterol Xinafoate; D013726:Terbutaline / Q000627:therapeutic use*; D013997:Time Factors; D014581:Urticaria / Q000139:chemically induced / Q000188:drug therapy*
D000318:Adrenergic beta-Agonists; D000888:Antibodies, Anti-Idiotypic; C026408:anti-IgE antibodies; D000068299:Salmeterol Xinafoate; D006632:Histamine; D013726:Terbutaline; D000420:Albuterol